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A B S T R A C T
Purpose
To determine whether cancer risks for carriers and noncarriers from families with a mismatch
repair (MMR) gene mutation are increased above the risks of the general population.
Patients and Methods
We prospectively followed a cohort of 446 unaffected carriers of an MMR gene mutation (MLH1,
n  161; MSH2, n  222; MSH6, n  47; and PMS2, n  16) and 1,029 their unaffected relatives
who did not carry a mutation every 5 years at recruitment centers of the Colon Cancer Family
Registry. For comparison of cancer risk with the general population, we estimated country-, age-,
and sex-specific standardized incidence ratios (SIRs) of cancer for carriers and noncarriers.
Results
Over a median follow-up of 5 years, mutation carriers had an increased risk of colorectal cancer
(CRC; SIR, 20.48; 95% CI, 11.71 to 33.27; P  .001), endometrial cancer (SIR, 30.62; 95% CI,
11.24 to 66.64; P  .001), ovarian cancer (SIR, 18.81; 95% CI, 3.88 to 54.95; P  .001), renal
cancer (SIR, 11.22; 95% CI, 2.31 to 32.79; P  .001), pancreatic cancer (SIR, 10.68; 95% CI, 2.68
to 47.70; P  .001), gastric cancer (SIR, 9.78; 95% CI, 1.18 to 35.30; P  .009), urinary bladder
cancer (SIR, 9.51; 95% CI, 1.15 to 34.37; P  .009), and female breast cancer (SIR, 3.95; 95% CI,
1.59 to 8.13; P .001). We found no evidence of their noncarrier relatives having an increased risk
of any cancer, including CRC (SIR, 1.02; 95% CI, 0.33 to 2.39; P  .97).
Conclusion
We confirmed that carriers of an MMR gene mutation were at increased risk of a wide variety of
cancers, including some cancers not previously recognized as being a result of MMR mutations,
and found no evidence of an increased risk of cancer for their noncarrier relatives.
J Clin Oncol 30:958-964. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Lynch syndrome is an autosomal dominant inher-
ited disorder of cancer susceptibility caused by
germline mutations in the DNA mismatch repair
(MMR) genes MLH1, MSH2, MSH6, and PMS2.
Estimates of carrier frequency of germline muta-
tions of these genes in the population range widely
depending on various assumptions, from approxi-
mately one in 3,010 individuals (for MLH1 and
MSH2 combined1) to one in 360 individuals (for all
fourMMRgenes combined2).Mutation carriers are
at substantially increased riskof cancersof the colon,
rectum, endometrium, stomach,ovary, ureter, renal
pelvis, brain, small bowel, and hepatobiliary tract,
and the diagnoses of these cancers generally occur at
younger ages than for the general population.3 Esti-
mates of site-specific cancer risks for MMR gene
mutation carriers inform optimal clinical manage-
ment. Screening colonoscopy,4,5 prophylactic hys-
terectomy, and bilateral salpingo-oophorectomy6
have the potential to decrease the risk of colorectal
cancer (CRC), endometrial cancer (EC), and ovar-
ian cancer, respectively, for MMR gene mutation
carriers. All studies estimating the risk of cancer for
MMR gene mutation carriers have been retrospec-
tive and, therefore, may be biased as a result of dif-
ferential recall of family history of cancer and failure
to adjust for ascertainment of subjects recruited be-
cause of a family history of cancer.7 Risk estimates
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using prospective data ofmutation carriers with no prior diagnosis
of cancer will not be biased but are challenging because they
require long-term follow-up to provide sufficient time for cancers
to be diagnosed.
Genetic testing of family members of a mutation carrier will
identify relatives who have and who have not inherited the family-
specificMMRgenemutation. It is not knownwhether the cancer risk
for noncarriers from families with MMR gene mutations is greater
than that of the general population. A family history of CRC increases
an individual’s risk 1.5- to eight-fold, varying with the number and
ages of affected relatives anddegree of relationship to theproband.8 In
Lynch syndrome families, it is possible thatmodifier genes participate
in themilieu inwhich cancermanifests.9-16Noncarriers ofMMRgene
mutations may share predisposing genetic risk with their mutation-
carrying relatives other than that caused by the MMR gene mutation
and therefore may be at increased risk compared with the general
population. If,however, theMMRmutationaccounts forall theexcess
cancer risks in these families, thennoncarriers shouldbeatpopulation
risk. In this study, we estimated cancer risks formutation carriers and
noncarriers, who had no prior diagnosis of cancer, from families with
MMRgenemutations fromtheColonCancerFamilyRegistry, usinga
prospective cohort.
PATIENTS AND METHODS
Colon Cancer Family Registry
This study, using the ColonCancer Family Registry, included carriers of
pathogenicMMRgenemutations and their noncarrier relatives. Details of the
Colon Cancer Family Registry have been published previously17 and can be
found at the National Cancer InstituteWeb site (http://epi.grants.cancer.gov/
CFR/). Families were recruited between 1997 and 2010 and were ascertained
viaCRCcases identified frompopulation cancer registries in theUnited States
(Washington, California, Arizona, Minnesota, Colorado, New Hampshire,
North Carolina, and Hawaii), Australia (Victoria), and Canada (Ontario) or
from family cancer clinics in the United States (Mayo Clinic, Rochester, MN,
andClevelandClinic,Cleveland,OH),Australia (Melbourne,Adelaide, Perth,
Brisbane, and Sydney), andNewZealand (Auckland).Written informed con-
sent was obtained from all study participants, and the study protocol was
approved at each center.
Data Collection
At recruitment, baseline information on demographics, personal char-
acteristics, personal and family history of cancer, cancer screening history,
history of polyps, polypectomy, hysterectomy, and other surgeries was ob-
tained from all participants. This participant information was updated ap-
proximately 5 and 10 years after baseline. Reported cancer diagnoses and ages
at which these occurred were confirmed, where possible, using pathology
reports,medical records, cancer registry reports, and/or death certificates. The
location, histology, and behavior of cancer diagnoses were coded using Inter-
national Classification ofDiseases forOncology (ICD-O).18 Blood and tumor
tissue samples were collected for genetic testing.
MMR Gene Mutation Testing
MMR gene mutation testing was performed by Sanger sequencing or
denaturing high-performance liquid chromatography, followed by confirma-
tory DNA sequencing. Large duplications and deletions were detected by
multiplex ligation-dependent probe amplification.17,19-21Mutation classifica-
tion and nomenclature were determined using the InSiGHT Colon Cancer
GeneVariantDatabase (http://www.insight-group.org/mutations), theMMR
genes variant database of the Memorial University of Newfoundland (http://
www.med.mun.ca/MMRvariants/),22 and the MMRGene Unclassified Vari-
ants Database (http://www.mmruv.info).23 Pathogenic mutations were
defined as variants resulting in a stop codon, frameshiftmutation, large dupli-
cation or deletion, ormissensemutation previously reported within scientific
literature to be pathogenic.
Eligibility Criteria
For this study, we assembled three subcohorts to estimate risk of CRC
(CRC risk subcohort), risk of EC (EC risk subcohort), and risk of any other
cancer (other cancer risk subcohort; Fig 1). Participants were eligible for all
subcohorts if they had undergone genetic testing for their specific family
germline MMR gene mutation and were confirmed to be either a carrier or
noncarrier of this pathogenic mutation, had been followed up at least once
since recruitment, and had no cancer diagnosis before or at the time of
recruitment. A total of 81 carriers and 126noncarrierswere excluded from the
CRC risk subcohort because they had a polypectomy before or at the time of
recruitment. A total of 26 carriers and 46 noncarriers were excluded from the
EC risk subcohort because they had a hysterectomy before or at the time of
recruitment (Fig 1). For this analysis we did not have information on which
participantswere awareof theirmutation statusorwhen theybecameawareof
their status in part because testingmayhave been conducted clinically, outside
the scope of the study.
Statistical Analysis
Observation time began at completion of the baseline questionnaire and
ended at the cancer diagnosis, death, or last follow-up, whichever occurred
first. ForCRCrisk,wecensored individuals at the timeofpolypectomy(except
when it occurred within a year before the CRC diagnosis, in which case we
assumed polypectomy was for the initial CRC diagnosis), and for EC risk, we
censored each woman at the time of hysterectomy.
Observed numbers of cancer diagnoses were divided by the expected
numbers of cancer diagnoses to calculate standardized incidence ratios (SIRs).
Expected numbers of cancer diagnoses were calculated by multiplying the
age-, sex-, and country-specific incidence for the general population by the
corresponding observation time in the study cohort. Country-, age-, and
sex-specific cancer incidences for the general populationwere obtained for the
period from 1998 to 2002 from Cancer Incidence in Five Continents.24 This
5-year period was selected as the closest available data set with respect to the
mean calendar year of cancer diagnoses of the sample, and given that it
averaged incidence over the 5-year period, it providesmore stable estimates of
incidence, especially for less common cancers. For cancer cases from the same
family, the jackknifemethodwasused to calculate 95%CIsby allowing for any
correlation of risk between relatives from the same family25; otherwise, we
used exact methods assuming that observed cancer cases followed a Pois-
son distribution.
We estimated SIRs for the following cancers observedmore thanonce in
carriers and noncarriers: colon and/or rectum (ICD-OC18 to C20), pancreas
(ICD-O C25), stomach (ICD-O C16), kidney and renal pelvis (ICD-O C64
and C65), urinary bladder (ICD-O C67), and lung (ICD-O C34) for both
sexes; endometrium (ICD-O C54 and C55), ovary (ICD-O C56), and breast
(ICD-OC50) for females; and prostate (ICD-OC61) for males.
Kaplan-Meier statisticswere used to estimate age-dependent cumulative
risk (penetrance) at 5 and 10 years. All reported statistical tests were two-sided
and P  .05 was considered statistically significant. STATA version 11.0
(STATA, College Station, TX)26 was used for all statistical analyses.
RESULTS
Selection of eligible carriers and noncarriers of an MMR gene muta-
tion from the Colon Cancer Family Registry for each cancer-specific
analysis to estimate risk of CRC, EC, and other cancers is depicted in
Figure 1.
CRC Risk Subcohort
This subcohort included 365 carriers and 903 noncarriers from
284 families withMMRgenemutations (Table 1).Of the 365 carriers,
310 (85%) were first-degree relatives, 50 (14%) were second-degree
relatives, and five (1%) were third-degree relatives of patients with
Cancer Risks for MMR Gene Mutation Carriers and Noncarriers
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CRC. Of the 903 noncarriers, 583 (64%) were first-degree relatives,
169 (19%) were second-degree relatives, and 151 (17%) were third-
degree relatives of patients with CRC.
Overamedian follow-upof5years, 16mutationcarriers (MLH1,
n9;MSH2, n4;MSH6, n2;PMS2, n1)werediagnosedwith
CRC at amedian age of 49 years (incidence rate, 8.84; 95%CI, 5.42 to
14.43 per 1,000 person-years; SIR, 20.48; 95% CI, 11.71 to 33.27;
P .001; Table 2). The CRC SIRs for carriers of specific MMR gene
mutationswere 39.40 (95%CI, 18.02 to 74.80) forMLH1, 10.76 (95%
CI, 2.93 to 27.55) forMSH2, 17.19 (95%CI, 2.08 to 62.10) forMSH6,
and 15.47 (95%CI, 0.39 to 86.21) for PMS2.
Five noncarriers were diagnosedwith CRC at amedian age of 60
years (incidence rate, 1.01; 95% CI, 0.42 to 2.44 per 1,000 person-
years). The overall SIR for noncarriers was 1.02 (95%CI, 0.33 to 2.39;
P .97). All of these CRCs were observed in first-degree relatives of
patients with CRC. The SIR was 1.43 (95% CI, 0.46 to 3.34) when
analysiswas restricted tononcarrierswhowerefirst-degree relatives of
patients with CRC.
Cumulative risks of CRCwere 4.14% (95%CI, 2.35% to 7.24%)
at 5 years and 8.05% (95% CI, 4.46% to 14.29%) at 10 years of
prospective follow-up for carriers and 0.39% (95% CI, 0.12% to
1.20%) at 5 years and 2.04% (95%CI, 0.49% to 8.30%) at 10 years for
noncarriers (Fig 2 and Table 3).
The frequency of colonoscopy screening was not different be-
tween individuals without CRC (unaffected) and those with CRC
(affected). On average, unaffected carriers were screened once every
2.7 years (95% CI, 2.5 to 3.0 years), whereas affected carriers were
screened every 2.5 years (95%CI, 1.4 to 3.5 years;P .63).Unaffected
noncarriers were screened every 3.9 years (95% CI, 3.7 to 4.1 years),
whereas affected noncarriers were screened every 3.9 years (95%CI, 0
to 8.6 years; P .98). Colonoscopy during the follow-up period for
carriers andnoncarriers is shown inAppendixTableA1 (online only).
EC Risk Subcohort
This female subcohort included 215 carriers and 523 noncarriers
from 229 families with MMR gene mutations (Table 1). Over a me-
dian follow-up of 5 years, six carriers were diagnosed with EC at a
median age of 53 years (incidence rate, 5.66; 95%CI, 2.54 to 12.59 per
1,000 person-years). The corresponding SIR was 30.62 (95% CI,
11.24 to 66.64; P .001) for carriers of any MMR gene mutation
(Table 2). EC was diagnosed in twoMLH1mutation carriers (SIR,
27.18; 95% CI, 6.80 to 108.66) and four MSH2 mutation carriers
(SIR, 44.92; 95% CI, 16.86 to 119.68). Cumulative risks were
estimated to be 2.84 (95%CI, 1.06 to 7.46) at 5 years and 9.84 (95%
CI, 3.45 to 26.33) at 10 years of prospective follow-up (Table 3). No
EC was observed in noncarriers.
Other Cancer Risk Subcohort
This subcohort included 446 carriers and 1,029noncarriers from
300 families with MMR gene mutations (Table 1). Over a median
follow-up of 5 years, for carriers, we observed three ovarian cancers
(SIR, 18.81; 95%CI, 3.88 to 54.95;P .001), three renal cancers (two
kidney cancers andone renal pelvis cancer; SIR, 11.22; 95%CI, 2.31 to
32.79; P .001), two pancreatic cancers (SIR, 10.68; 95% CI, 2.68 to
47.70;P .001), two gastric cancers (SIR, 9.78; 95%CI, 1.18 to 35.30;
P  .009), two urinary bladder cancers (SIR, 9.51; 95% CI, 1.15 to
34.37; P .009), seven female breast cancers (SIR, 3.95; 95%CI, 1.59
to 8.13; P  .001), and three prostate cancers (Table 2). Cancers
observed in only one carrier each included cancer of the esophagus
(ICD-O C15.9), biliary tract (ICD-O C24.0), liver (ICD-O C22.1),
Carriers (n = 365)
  Censored at age of
    Cancer diagnosis (n = 37)
    Polypectomy (n = 29)
    Last contact (n = 299)
    Death (n = 0)
Noncarriers (n = 903)
  Censored at age of
    Cancer diagnosis (n = 31)
    Hysterectomy (n = 33)
    Last contact (n = 823)
    Death (n = 16)
Carriers (n = 215)
  Censored at age of
    Cancer diagnosis (n = 25)
    Hysterectomy (n = 15)
    Last contact (n = 175)
    Death (n = 0)
Noncarriers (n = 523)
  Censored at age of
    Cancer diagnosis (n = 13)
    Hysterectomy (n = 24)
    Last contact (n = 478)
    Death (n = 8)
Excluded 81 carriers and 
126 noncarriers who underwent
polypectomy before or at
recruitment
Excluded 205 men carriers and 
442 men who were noncarriers,* 
as well as 26 women carriers 
and 64 women who were 
noncarriers and who underwent 
hysterectomy before or at 
recruitment
Eligible (N = 1,475)
   Carrier (n = 446)
   Noncarrier (n = 1,029)
Carriers (n = 446)
  Censored at age of
    Cancer diagnosis (n = 57)
    Last contact (n = 389)
    Death (n = 0)
Noncarriers (n = 1,029)
  Censored at age of
    Cancer diagnosis (n = 38)
    Last contact (n = 974)
    Death (n = 17)
CRC risk subcohort EC risk subcohort Other cancer risk subcohort
Fig 1. Flow diagram of the selection of
carriers and noncarriers of a mismatch
repair gene mutation. CRC, colorectal can-
cer; EC, endometrial cancer. (*) Although
the EC risk cohort was composed of
women, a note of clarification with re-
spect to the men excluded from this
group is provided.
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adrenal gland (ICD-O C74.9), small intestine (ICD-O C17.9), and
ureter (ICD-OC66.9).
For noncarriers, there was no evidence of an increased risk of
lung, breast, and prostate cancers. In noncarriers, we also observed
one case each of pancreatic (ICD-O C25.9), urinary bladder (ICD-O
C67.9), thyroid (ICD-OC73.9), and esophageal (ICD-O C15.9) can-
cer (Table 2).
DISCUSSION
We confirmed that MMR gene mutation carriers were at increased
risk of a wide variety of cancers and found that there was no evidence
of an increased risk of cancer for their noncarrier relatives. A major
strength of our study is the prospective nature of the design, because
observation time for carriers andnoncarriers commencedbefore can-
cer diagnosis. This design, therefore, avoided ascertainment bias com-
monlypresent in retrospectiveanalyses,particularlywhenestimatesof
cancer risk aremade using relatives who are enrolled in cancer clinics
because they have been diagnosed with cancer. A further strength of
the prospective analysis is that it provides an estimate, based on em-
pirical data, of future cancer risk at the time they come under clinical
care.Our estimated 10-year risk ofCRC for carrierswith amedian age
of 49 years (8.05%; 95% CI, 4.46% to 14.29%) is comparable to our
previous estimate (using an ascertainment-corrected retrospective
analysis) of the10-year risk forMSH6mutationcarriers at age50years
(6% [95% CI, 3% to 9%] for men and 3% [95% CI, 1% to 5%] for
women).27 It seems to be lower than a previous retrospective estimate
of the 10-year estimates forMLH1 andMSH2 carriers (26% for men
and 13% for women).28
An unanticipated finding of our study is the confirmation of an
increased risk for cancers of the breast and pancreas for MMR gene
mutation carriers. Although risk of pancreatic cancer has been inves-
tigated in Lynch syndrome,29-33 the evidence was inconsistent. The
study showing evidence for an associationwas that ofKastrinos et al,34
which recently showed an increased risk of pancreatic cancer in Lynch
syndrome (hazard ratio, 8.6; 95% CI, 4.5 to 15.7). This result is con-
sistent with our finding (test for difference, P .79). However, given
the limited evidence for efficacy of screening for pancreatic cancers,35
expert opinion has not yet advocated pancreatic cancer screening in
the context of Lynch syndrome.
Table 1. Baseline Demographics and Clinical Characteristics of Carriers and Noncarriers of a Mismatch Repair Gene Mutation
Demographic or Clinical Characteristic
CRC Risk Subcohort EC Risk Subcohort Other Cancer Risk Subcohort
Carriers
(n  365)
Noncarriers
(n  903)
Carriers
(n  215)
Noncarriers
(n  523)
Carriers
(n  446)
Noncarriers
(n  1,029)
No. % No. % No. % No. % No. % No. %
MMR gene mutated
MLH1 134 37 87 41 161 36
MSH2 178 49 105 49 222 50
MSH6 40 11 18 8 47 11
PMS2 13 3 5 2 16 3
Sex
Female 201 55 523 58 215 100 523 100 241 54 587 57
Male 164 45 380 42 — — 205 46 442 43
Race
White 346 96.4 847 96.3 205 97.2 488 96 423 96.4 965 96
Latino/Hispanic 1 0.3 13 1.5 1 0.5 7 1 4 0.9 17 2
Asian 9 2.5 8 0.9 3 1.4 5 1 9 2.0 9 1
Middle Eastern 2 0.6 5 0.6 2 0.9 4 1 2 0.5 6 1
Other 1 0.3 7 0.8 0 0 5 1 1 0.2 7 1
Unknown 6 23 4 14 7 25
Country of recruitment
Canada 24 6 27 3 9 4 23 4 24 5 30 3
United States 50 14 110 12 31 14 69 13 75 17 135 13
Australasia 291 80 766 85 175 81 431 82 347 78 864 84
Source of ascertainment
Population based 59 16 135 15 35 16 77 15 71 16 154 15
Clinic based 306 84 768 85 180 84 446 85 375 84 875 85
Age at recruitment, years
Mean 39.9 48.3 39.8 47.3 41.3 48.9
SD 13.8 15.6 13.1 15.9 13.9 15.4
Follow-up
Total person-years 1,809 4,930 1,061 2,848 2,365 5,880
Mean, years 5.0 5.5 4.9 5.5 5.3 5.7
SD, years 2.5 2.5 2.5 2.5 2.4 2.5
Median, years 4.9 5.4 4.8 5.4 5.2 5.6
Range, years 0.3-11.2 0.1-11.9 0.2-11.2 0.2-11.9 0.4-11.2 0.1-11.9
Abbreviations: CRC, colorectal cancer; EC, endometrial cancer; SD, standard deviation.
Cancer Risks for MMR Gene Mutation Carriers and Noncarriers
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Amore controversial associationwith Lynch syndrome is that of
breast cancer. Initially raised by Lynch et al36 several decades ago, the
issue of breast cancer risk in Lynch syndrome has been debated with
evidence for and against this association. Multiple case reports de-
scribingMMR-deficient breast cancers, including cases ofmale breast
cancer, have been published.37-41Walsh et al40 showed that about half
of breast cancers observed inMMRgenemutation carries have loss of
expression in the tumor of the gene that is mutated in the germline.
However, this and other studies were not able to address whether the
MMR deficiency caused breast cancer or was a phenotype of a breast
cancer caused by another factor. In this report, we observed an in-
creased riskofbreast cancer forMMRgenemutationcarriers followed
prospectively. Although the numbers are small, the riskwas estimated
tobe increased four-foldabove thatof thegeneralpopulation, suggest-
ing that MMRmutation carriers may benefit from enhanced screen-
ing. Further clarification of age-specificmagnitude of risk is needed to
determine whether ages at screening or methods such as use of mag-
netic resonance imaging should bemodified in Lynch syndrome.
In addition to defining spectrumand cancer risks forMMRgene
mutation carriers, it is important to clarify the risk of CRC and other
cancers for noncarrier relatives. Identification of mutation noncarri-
ers is considered to be one of themajor benefits ofMMRgene testing,
providing reassurance that these people are at substantially lower risk
than their mutation-carrying relatives and, therefore, not subject to
the same costly, frequent, and invasive screening and risk-reduction
Table 2. Age-, Sex-, and Country-Specific SIRs and Corresponding 95% CIs by Cancer Site for Carriers and Noncarriers of a Mismatch Repair Gene Mutation
Compared With the General Population
Cancer Observed No. Expected No.
Age at Diagnosis
(years)
SIR 95% CI PMedian Range
Carriers
Colorectal cancer 16 0.78 49 26-75 20.48 11.71 to 33.27 .001
Endometrial cancer 6 0.20 53 42-66 30.62 11.24 to 66.64 .001
Ovary cancer 3 0.16 52 45-56 18.81 3.88 to 54.95 .001
Renal cancer 3 0.27 71 70-77 11.22 2.31 to 32.79 .001
Pancreas cancer 2 0.19 64 63-65 10.68 2.68 to 47.70 .001
Gastric cancer 2 0.20 59 31-88 9.78 1.18 to 35.30 .009
Urinary bladder cancer 2 0.21 62 55-68 9.51† 1.15 to 34.37 .009
Breast cancer‡ 7 1.77 56 42-62 3.95 1.59 to 8.13 .001
Prostate cancer 3 1.21 54 50-62 2.49 0.51 to 7.27 .18
Noncarriers
Colorectal cancer 5 4.88 60 55-73 1.02 0.33 to 2.39 .97
Lung cancer 3 4.68 69 46-75 0.64 0.13 to 1.87 .51
Breast cancer‡ 5 6.95 59 52-75 0.72 0.23 to 1.68 .52
Prostate cancer 9 5.53 67 57-82 1.63 0.74 to 3.09 .18
Abbreviation: SIR, standardized incidence ratio.
Kidney and renal pelvis.
†Adjusted for family using Jackknife method.
‡For females only.
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Fig 2. Kaplan-Meier curves for cumulative risks and their corresponding 95%
CIs of colorectal cancer at 5 and 10 years.
Table 3. Cumulative Risk of Cancer Over 5 and 10 Years and Corresponding
95% CIs for Carriers and Noncarriers of a Mismatch Repair Gene Mutation
Who Had No Previous Diagnosis of Cancer at Baseline
Cancer
5 Years 10 Years
Cumulative
Risk (%) 95% CI (%)
Cumulative
Risk (%) 95% CI (%)
Carriers
Colorectal cancer 4.14 2.35 to 7.24 8.05 4.46 to 14.29
Endometrial cancer 2.84 1.06 to 7.46 9.84 3.45 to 26.33
Ovary cancer 0.29 0.04 to 20.5 3.11 0.82 to 11.43
Renal cancer 0.80 0.26 to 2.45 —
Pancreas cancer 0.33 0.05 to 2.34 0.95 0.22 to 3.97
Gastric cancer 0.53 0.13 to 2.10 —
Urinary bladder
cancer 0.28 0.04 to 1.97 2.71 0.47 to 14.93
Breast cancer† 0.85 0.27 to 2.65 4.49 1.78 to 11.08
Noncarriers
Colorectal cancer 0.39 0.12 to 1.20 2.04 0.49 to 8.30
Kidney and renal pelvis.
†For females only.
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strategies. Because no cancer arises, to our knowledge, as a result of a
single gene mutation, even highly penetrant disorders such as Lynch
syndrome might arise on the background of multiple other genetic
variants thatmodify cancer risks. If that is the case, then relatives who
do not carry the family-specific pathogenic MMRmutation may still
have a cancer risk that is elevated compared with the general popula-
tion. In this study,we foundnoevidenceof an increasedriskof cancers
for the noncarrier relatives, whereas carriers of an MMR gene muta-
tion from the same families were at increased risk of a wide variety of
cancers. In a similar scenario, it has been observed that there is no
evidence of increased risk of breast cancer42,43 or ovarian cancer44 for
noncarriers from families carryingmutations of BRCA1 or BRCA2.
Estimating penetrance for CRC is particularly challenging in the
high-risk family settingbecause surveillancecolonoscopy is likely tobe
offered to those with a strong family history of CRC or if Lynch
syndrome has been diagnosed in a relative. The colonoscopy likely
changes the natural history of the disease by removing the precursor
lesion at least some of the time. We observed that those who were
mutation carriers (although they may not have known about their
mutation status at the time) were having frequent colonoscopies (ap-
proximately once every 3 years) yet still manifested an appreciable
high risk for development of CRC. In contrast, those who were not
mutation carriers (although they also may not have known of their
mutation status) were also having colonoscopies almost as frequently
as the carriers (approximately once every 4 years). Therefore, we
cannot dismiss the possibility that noncarriers who are relatives of
mutation carriers are at increased risk of CRC, but their frequent
colonoscopies may have reduced their risk.
We also found no evidence of increased risk of extracolonic
cancers for the noncarriers. It is unlikely that this finding can be
attributed to increased screening for these cancers because, unlike
CRC, screening does not alter the risk for extracolonic cancers. For
example, screening for urothelial, endometrial, and ovarian cancers
does not reduce the risk of these diseases, because it is done for early
detectiononly andnot for removal ofprecursor lesions, and therefore,
screening would not influence the estimates of these cancer risks.
There are some limitations to our study, most notably the small
number of events and a short follow-up duration. We do not have
sufficient power to exclude a two-fold increased risk of CRC for the
noncarriers. Another possible limitation is that censoring each indi-
vidual at the age of polypectomy could have resulted in underestimat-
ing the true cancer risk.
In conclusion, our prospective analysis provides unbiased
estimates of cancer risks for MMR gene mutation carriers, includ-
ing significantly increased risks of recognized Lynch syndrome–
associated cancers (colorectal, endometrial, ovarian, renal, gastric,
and urinary bladder) and of breast cancer and pancreatic cancer.
For the noncarrier relatives of family-specific MMR gene muta-
tions, we foundno evidence that their risks of CRCor other cancers
exceed the population risks.
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